Partnerships
Bringing the ImmTOR® and ImmTOR-IL™ precision immune tolerance platform to diverse indications
Why we partner
The potentially broad applicability of the ImmTOR® and ImmTOR-IL™ platform provides the unique ability to address immunogenicity across a range of indications and in combination with a variety of therapeutic approaches. We believe this technology deserves to have a broad patient reach and we are open to developing strategic partnerships, research collaborations and licensing arrangements.
Our Partnerships
Selecta has entered strategic transactions with leading biopharmaceutical companies to further expand our broad and diversified pipeline.
Immtor Approach
Agreement
Indications
2022
Immtor Approach
GENE THERAPY
Agreement
Strategic licensing agreement to develop next-generation AAV Capsids
Indications
Undisclosed
2021
Immtor Approach
BIOLOGIC
Agreement
Strategic licensing agreement to develop targeted, next-generation enzyme therapies
Indications
Undisclosed
2021
Immtor Approach
GENE THERAPY
Agreement
Strategic licensing agreement to enable the dosing of gene therapies
Indications
AAV Mediated Gene Therapies
2021
Immtor Approach
GENE THERAPY
Agreement
Strategic licensing agreement to develop targeted, next-generation gene therapies
Indications
Lysosomal storage disorders
2021
Immtor Approach
AUTOIMMUNE
Agreement
Collaboration to engineer proprietary IL-2 protein agonists
Indications
Autoimmune and deleterious immune indications
2020
Immtor Approach
GENE THERAPY
Agreement
Research Option and License Agreement (Global)
Indications
Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes
2020
Immtor Approach
BIOLOGIC
Agreement
License Agreement (Global, excluding China)
Indications
Chronic refractory gout
2019
Immtor Approach
GENE THERAPY
Agreement
License Agreement
Indications
Pompe disease
Partner with us
Connect with us about partnership opportunities
We are open to discussing opportunities both for partners to use our ImmTOR® and ImmTOR-ILTM platform for their own therapies as well as for us to bring additional therapies in house. Selecta is also looking for partnerships to unlock the potential of its proprietary IgG protease, Xork, for the mitigation of pre-existing anti-AAV antibodies.
